keyword
MENU ▼
Read by QxMD icon Read
search

Low Grade Metastatic Thymoma

keyword
https://www.readbyqxmd.com/read/25354884/adrenocorticotropic-hormone-producing-thymic-neuroendocrine-carcinoma-with-oncocytic-features-a-case-report-and-review-of-literature
#1
REVIEW
Nadja K Falk, Annikka Weissferdt, Mouhammed A Habra, Sinchita Roy-Chowdhuri
Thymic neuroendocrine carcinomas are the most common mediastinal neuroendocrine tumor. These malignancies are not often diagnosed by fine-needle aspiration (FNA), as they are more commonly diagnosed by biopsy or excision. We describe a case of a FNA of a paratracheal mass from a 38-year-old man who presented with Cushing syndrome. A low-grade neuroendocrine carcinoma with oncocytic features was diagnosed, which was later confirmed by excision of the thymus, anterior mediastinal and paratracheal soft tissue, and lymph nodes...
April 2015: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/24065624/first-in-human-pharmacokinetic-and-pharmacodynamic-phase-i-study-of-resminostat-an-oral-histone-deacetylase-inhibitor-in-patients-with-advanced-solid-tumors
#2
André T Brunetto, Joo Ern Ang, Rohit Lal, David Olmos, L Rhoda Molife, Rebecca Kristeleit, Ann Parker, Isabel Casamayor, Muyibat Olaleye, Anna Mais, Bernhard Hauns, Vera Strobel, Bernd Hentsch, Johann S de Bono
PURPOSE: This first-in-human dose-escalating trial investigated the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and pharmacodynamics of the novel histone deacetylase (HDAC) inhibitor resminostat in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Resminostat was administered orally once-daily on days 1 to 5 every 14 days at 5 dose levels between 100 and 800 mg. Safety, pharmacokinetics, pharmacodynamics including histone acetylation and HDAC enzyme activity, and antitumor efficacy were assessed...
October 1, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/23352916/lung-metastases-treated-with-image-guided-stereotactic-body-radiation-therapy
#3
A M Baschnagel, V S Mangona, J M Robertson, R J Welsh, L L Kestin, I S Grills
AIMS: To evaluate outcomes after treatment with image-guided stereotactic body radiation therapy (SBRT) using daily online cone beam computed tomography for malignancies metastatic to the lung. MATERIALS AND METHODS: Forty-seven lung metastases in 32 patients were treated with volumetrically guided SBRT. The median age was 62 years (21-87). Primaries included colorectal (n = 10), sarcoma (n = 4), head and neck (n = 4), melanoma (n = 3), bladder (n = 2), non-small cell lung cancer (n = 2), renal cell (n = 2), thymoma (n = 2), thyroid (n = 1), endometrial (n = 1) and oesophageal (n = 1)...
April 2013: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/16162976/a-phase-i-and-pharmacokinetic-study-of-the-selective-non-peptidic-inhibitor-of-matrix-metalloproteinase-bay-12-9566-in-combination-with-etoposide-and-carboplatin
#4
Julian R Molina, Joel M Reid, Charles Erlichman, Jeff A Sloan, Alfred Furth, Stephanie L Safgren, Chetan D Lathia, Steven R Alberts
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade the extracellular matrix during the processes of invasion, metastasis and angiogenesis. BAY 12-9566 (BAY) is a selective, non-peptidic biphenyl inhibitor of MMPs, with nanomolar inhibitory activity against MMP-2, -3 and -9, and anti-invasive, anti-metastatic and anti-angiogenic activity in a variety of tumor models. This phase I study of oral BAY was conducted to evaluate the safety and pharmacokinetics of BAY when administered in combination with etoposide (VP-16) or in combination with VP-16 and carboplatin (CBDCA) in subjects with advanced cancer...
October 2005: Anti-cancer Drugs
https://www.readbyqxmd.com/read/14758136/multimodality-therapy-for-thymic-carcinoma-tca-results-of-a-30-year-single-institution-experience
#5
Francisco J Hernandez-Ilizaliturri, Dongfeng Tan, David Cipolla, Gregory Connolly, George Debb, Nithya Ramnath
The aim of this study was to correlate the clinicopathologic features and therapeutic approaches with the outcome of patients with thymic carcinoma (TCA), an aggressive, uncommon malignancy of the anterior mediastinum. TCA is morphologically distinct from thymoma, a cytologically bland, often encapsulated, locally invasive, rarely metastatic tumor. The Roswell Park Cancer Institute tumor registry was used to identify patients with TCA or invasive thymic neoplasm of the epithelial type (TNET). Between 1971 and 2001, 22 patients had a pathologic diagnosis of TCA and/or TNET...
February 2004: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/9669349/papillary-carcinoma-of-the-thymus-report-of-four-cases-of-a-new-microscopic-type-of-thymic-carcinoma
#6
Y Matsuno, N Morozumi, S Hirohashi, Y Shimosato, J Rosai
We describe four cases of papillary carcinoma arising in the thymus. Three showed low-grade atypia and were associated with spindle cell-type thymoma. The fourth case showed high-grade atypia and had no evidence of an association with thymoma. Two of three low-grade cases invaded the lung and showed extensive lymphatic permeation. Cyst formation was seen in one case. Immunohistochemically, the tumor cells were positive for carcinoembryonic antigen (CEA), Leu-M1, Ber-EP4, calretinin (2 cases), and CD5 and were negative for thyroglobulin and pulmonary surfactant apoprotein...
July 1998: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/9543665/intrathyroidal-epithelial-thymoma-itet-carcinoma-showing-thymus-like-differentiation-castle-exhibits-cd5-immunoreactivity-new-evidence-for-thymic-differentiation
#7
D M Dorfman, A Shahsafaei, A Miyauchi
AIMS: Cases of intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) were examined for CD5 immunoreactivity, a feature of true thymic carcinoma, but not other thymic epithelial neoplasms or carcinomas of other sites. ITET/CASTLE, a rare, low-grade malignant neoplasm arising within the thyroid gland which resembles lymphoepithelioma-like and squamous cell carcinoma of the thymus, is postulated to arise from remnants of branchial pouch capable of thymic differentiation, but thymic differentiation in this neoplasm remains unproven...
February 1998: Histopathology
https://www.readbyqxmd.com/read/8033141/phase-i-trial-of-recombinant-macrophage-colony-stimulating-factor-and-recombinant-gamma-interferon-toxicity-monocytosis-and-clinical-effects
#8
L M Weiner, W Li, M Holmes, R B Catalano, M Dovnarsky, K Padavic, R K Alpaugh
Macrophage colony-stimulating factor (M-CSF) is a known inducer of proliferation and differentiation of cells of the mononuclear phagocyte lineage, and gamma-interferon (gamma-IFN) is a known activator of mononuclear phagocytes. In this Phase I clinical trial of combined therapy with M-CSF and gamma-IFN, 36 patients were treated with 14-day continuous infusions of M-CSF at doses ranging from 10 to 140 micrograms/kg/day. In all but five patients, gamma-IFN was administered by daily s.c. injection on days 8-14 of the M-CSF infusion at doses of 0...
August 1, 1994: Cancer Research
https://www.readbyqxmd.com/read/4092582/-thymoma-report-of-268-cases
#9
J A Luo
This paper reports 268 cases of thymoma treated by surgery and followed up to 24 years in our hospital. We believe that thymoma is a low grade malignancy. The gross findings on thoracotomy and microscopic examination are useful for diagnosis. The prognosis is related to the morphology of the tumor capsule. For patients with noninvasive thymoma, the prognosis is excellent and the recurrence rate is the lowest. In spite of a benign histologic feature, the prognosis is poor for patients with invasive thymoma which gave a 5 and 10 year survival rate of 65...
September 1985: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/2623740/evaluation-of-prognostic-features-in-thymic-epithelial-tumors
#10
T Kirchner, B Schalke, A Marx, H K Müller-Hermelink
Based on the original proposals of Müller-Hermelink [3,8] and the study of 95 tumor specimens from the files of our institute we have established a new concept for the classification of thymic epithelial tumors. Thymomas are related to the structural components of normal thymus and divided in medullary, mixed, predominantly cortical and cortical types. In addition a well-differentiated thymic carcinoma with partial loss of organotypic differentiation is characterized and distinguished from other carcinoma types with total lack of specific thymic features...
1989: Thymus
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"